The systemic delivery of an antisense molecule to ID1, peptide conjugate antisense oligonucleotide (ID1-PCAO), can effectively reduce ID1 protein levels in tumor endothelium to inhibit primary tumor growth and metastatic spread of lung cancer and breast cancer. This evidence concerns the gene ID1 and lung carcinoma.